References
- 1. Gołos A, Jesionek-Kupnicka D, Gil L, Braun M, Komarnicki M, Robak T, et al. The Expression of the SLIT-ROBO Family in Adult Patients with Acute Myeloid Leukemia. Arch Immunol Ther Exp (Warsz). 2019;67(2):109-23. DOI: 10.1007/s00005-019-00535-8642049230820596
- 2. Ueda N, Fujita K, Okuno Y, Nakatani K, Mio T. Therapy-related acute myeloid leukemia after chemotherapy in extensive disease-small cell lung cancer. Clin Case Rep. 2018;7(1):100-3. DOI: 10.1002/ccr3.1931633274130656018
- 3. He X, Li W, Liang X, Zhu X, Zhang L, Huang Y, et al. IGF2BP2 Overexpression Indicates Poor Survival in Patients with Acute Myelocytic Leukemia. Cell Physiol Biochem. 2018;51(4):1945-56. DOI: 10.1159/00049571930513526
- 4. Prochazka KT, Pregartner G, Rücker FG, Heitzer E, Pabst G, Wölfler A, et al. Clinical implications of subclonal TP53 mutations in acute myeloid leukemia. Haematologica. 2019;104(3):516-23. DOI: 10.3324/haematol.2018.205013639534130309854
- 5. Stomper J, Ihorst G, Suciu S, Sander PN, Becker H, Wijermans PW, et al. Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome. Haematologica. 2019;104(1):59-69. DOI: 10.3324/haematol.2017.187278631201430171030
- 6. Wang F, Tian X, Zhou J, Wang G, Yu W, Li Z, et al. A three lncRNA signature for prognosis prediction of acute myeloid leukemia in patients. Mol Med Rep. 2018;18(2):1473-84. DOI: 10.3892/mmr.2018.9139607222029901168
- 7. Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2017 Edition). Zhonghua Xue Ye Xue Za Zhi. 2017;38(3):177-82.
- 8. Min JW, Koh Y, Kim DY, Kim HL, Han JA, Jung YJ, et al. Identification of novel functional variants of sin3a and srsf1 among somatic variants in acute myeloid leukemia patients. Mol Cells. 2018;41(5):465-75.
- 9. Ma L, Kuai WX, Sun XZ, Lu XC, Yuan YF. Long noncoding RNA LINC00265 predicts the prognosis of acute myeloid leukemia patients and functions as a promoter by activating PI3K-AKT pathway. Eur Rev Med Pharmacol Sci. 2018;22(22):7867-76.
- 10. Bani-Ahmad MA, Al-Sweedan SA, Al-Asseiri MA, Alkhatib AJ. A Proposed kinetic model for the diagnostic and prognostic value of wt1 and p53 in acute myeloid leukemia. Clin Lab. 2018;64(3):357-63. DOI: 10.7754/Clin.Lab.2017.17091529739109
- 11. Ollila TA, Olszewski AJ, Butera JN, Quesenberry MI, Quesenberry PJ, Reagan JL. Marrow hypocellularity, but not residual blast count or receipt of reinduction chemotherapy, is prognostic on day-14 assessment in acute myeloid leukemia patients with morphologic residual disease. Clin Lymphoma Myeloma Leuk. 2018;18(3):204-9. DOI: 10.1016/j.clml.2018.01.00729433979
- 12. Lacombe F, Campos L, Allou K, Arnoulet C, Delabarthe A, Dumezy F, et al. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia. Hematol Oncol. 2018;36(2):422-8. DOI: 10.1002/hon.248829218734
- 13. Khalil MMI, Lipton JH, Atenafu EG, Gupta V, Kim DD, Kuruvilla J, et al. Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia. Eur J Haematol. 2018;100(2):198-205. DOI: 10.1111/ejh.1300029168234
- 14. Zhou JD, Yao DM, Li XX, Zhang TJ, Zhang W, Ma JC, et al. KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia. Oncotarget. 2017;8(39):66087-97. DOI: 10.18632/oncotarget.19798563039429029494
- 15. Elhamamsy AR, El Sharkawy MS, Zanaty AF, Mahrous MA, Mohamed AE, Abushaaban EA. Circulating miR-92a, miR-143 and miR-342 in Plasma are Novel Potential Biomarkers for Acute Myeloid Leukemia. Int J Mol Cell Med. 2017;6(2):77-86.
- 16. Vidal V, Robert G, Goursaud L, Durand L, Ginet C, Karsenti JM, et al. BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia. Oncotarget. 2017;8(29):47103-9. DOI: 10.18632/oncotarget.17482556454728514758
- 17. Isidori A, Loscocco F, Curti A, Amadori S, Visani G. Genomic profiling and predicting treatment response in acute myeloid leukemia. Pharmacogenomics. 20: 467-470, 2019. DOI: 10.2217/pgs-2018-020231124415
- 18. McMahon CM, Canaani J, Rea B, et al. Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood Adv 2019;20(7):467-70. DOI: 10.1182/bloodadvances.2018029496653887031122910
- 19. Xiao PF, Tao YF, Hu SY, Cao L, Lu J, Wang J, et al. mRNA expression profiling of histone modifying enzymes in pediatric acute monoblastic leukemia. Pharmazie. 2017;72(3):177-86.
- 20. Chae HD, Cox N, Dahl GV, Lacayo NJ, Davis KL, Capolicchio S, et al. Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways. Oncotarget. 2017;9(4):4301-17. DOI: 10.18632/oncotarget.23794579697529435104
- 21. Safaei A, Monabati A, Mokhtari M, Safavi M, Solhjoo F. Evaluation of the CD123 Expression and FLT3 Gene Mutations in Patients with Acute Myeloid Leukemia. Iran J Pathol. 2018;13(4):438-46.
- 22. Elkeeb D, Hopkins Z, Miles RR, Halwani A, Wada D. Ominous cutaneous presentation of acute myeloid leukemia without peripheral blood involvement upon initial presentation and relapse: case report and literature review. Eur J Dermatol. 2018;28(6):809-17.
- 23. Alcalay M, Tiacci E, Bergomas R, Bigerna B, Venturini E, Minardi SP, et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood. 2005;106(3):899-902. DOI: 10.1182/blood-2005-02-056015831697
- 24. Au WY, Fung A, Chim CS, Lie AK, Liang R, Ma ES, et al. FLT-3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact. Br J Haematol. 2004;125(4):463-9. DOI: 10.1111/j.1365-2141.2004.04935.x15142116